Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5355-5362

  Huang, Shyhmin ^a   Armstrong, Eric A ^a   Benavente, Sergio ^a   Chinnaiyan, Prakash ^a   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; ERLOTINIB; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG TUMOR; MODULATION; MOLECULAR TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 3442891161     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0562     Document Type: Article

References (33)

1. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 1965;12:394-407.
2. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-7.
3. Anonymous. Iressa: first angiogenesis inhibitor approved for the treatment of advanced NSCLC. Expert Rev Anticancer Ther 2003;3:257.
4. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002;13(Suppl 5):2-3.
5. Johnson D. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT II) [abstract]. Ann Oncol 2002;13(Suppl5):127.
6. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
7. Reid S, Cross R, Snow EC. Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis. J Immunol Methods 1996;192:43-54.
8. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
9. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
10. Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40.
11. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 2002;62:122-8.
12. Ng SSW, Tsao M-S, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002;1:777-83.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
14. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
15. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic Med Chem Lett 2001;11:1911-4.
16. Matar P, Rojo F, Guzman M, Rodriguez-Viltro I, Arribas J, Baselga J. Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, "Iressa") and a monoclonal antibody (IMC-C225): evidence of synergy [abstract]. Proc Am Assoc Cancer Res 2003;44:800.
17. Dowlati A, Nethery D, Liu J. JAK Combined inhibition of epidermal growth factor receptor (EGFR) and JAK/Stat signaling results in superior growth inhibition in A431 cell line as compared to single agent therapy [abstract]. Proc Am Assoc Cancer Res 2003;44:800.
18. Huang S, Armstrong E, Chinnaiyan P, Harari PM. Dual agent molecular targeting of the epidermal growth factor receptor: combining anti-HER1/EGFR monoclonal antibody with tyrosine kinase inhibitor [abstract]. Proc Am Assoc Cancer Res 2003;44:3777.
19. Finn RS, Wilson CA, Sanders J, et al. Targeting the epidermal growth factor receptor (EGFR) and HER-2 with OSI-774 and trastuzumab, respectively, in HER-2 overexpressing human breast cancer cell lines results in a therapeutic advantage in vitro [abstract]. Proc Am Soc Clin Oncol 2003;22:235.
20. Kauh JS, Laguinge L, Lin S, Jessup JM. Combined tyrosine kinase inhibition of c-erb B-2 and EGFR in pancreatic adenocarcinoma leads to increased inhibition of cell growth [abstract]. Proc Am Soc Clin Oncol 2003;22:876.
21. Modjtahedi H, McNeela G, Thomas H. Characterization of a new anti-EGFR mAb raised against LNCaP cells and an investigation on the anti-tumor activity of anti-EGFR mAb in combination with anti-HER-2 mAb [abstract]. Proc Am Assoc Cancer Res 2003;44:151.
22. Saltz L, Meropol NJ, Loehrer PL, Waksal H, Needle MN, Mayer RJ. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract]. PTOC Am Soc Clin Oncol 2002;21:504.
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol 2003;22:252.
24. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10.
25. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
26. Hortobagyi GN, Sauter G. Challenges and opportunities for erlotinib (Tarceva): what does the future hold? Semin Oncol 2003;30:47-53.
27. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
28. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003;30:3-14.
29. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
30. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
31. Li B, Chang C-M, Yuan M, McKenna WG, Shu H-K. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003;63:7443-50.
32. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22.
33. She Q-B, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/ Akt pathway signaling. Clin Cancer Res 2003;9:4340-6.